Isabel Frahm
Sanatorio Mater Dei, B, Argentina
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.
Journal: NPJ breast cancer
Published: November 03, 2020
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.
Journal: The Journal of pathology
Published: February 06, 2020
Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.
Journal: BMC cancer
Published: June 16, 2017
TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 15, 2016
A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients.
Journal: SpringerPlus
Published: August 04, 2015
Targeting Stat3 induces senescence in tumor cells and elicits prophylactic and therapeutic immune responses against breast cancer growth mediated by NK cells and CD4+ T cells.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: July 04, 2012
Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer.
Journal: BMC cancer
Published: November 03, 2011
Alterations in c-Src/HER1 and estrogen receptor α signaling pathways in mammary gland and tumors of hexachlorobenzene-treated rats.
Journal: Toxicology
Published: October 05, 2011
Showing 1-8 of 8
Last Updated: 09/26/2026